European Union medical cannabis trade: Germany’s 50-tonne quarter shows a market still built on imports

Germany’s first quarter has become an EU-scale signal

For the European Union, Germany’s first-quarter import total matters because it turns what might look like a national statistic into a regional market signal. A single member state importing 50.539 tonnes in three months tells wholesalers, producers and regulators across Europe that the continent’s biggest medical channel is still absorbing very large volumes through the pharmacy system.

The scale is easier to grasp in the logistics chain itself:

Set beside the other numbers cited in the current reporting cycle, the quarter looks like this:

Those figures show why Germany has become the reference point for medical cannabis trade inside Europe. What would count as a full-year benchmark elsewhere has become a single-quarter number here, while the 12-month total above 218 tonnes suggests that import demand remains structurally large even as the legal landscape around it becomes more diverse.

An import market built through pharmacies and foreign supply

The present scale did not appear overnight. The primary source says medical cannabis has been available in German pharmacies since 2017, and that what began as a relatively limited patient-access programme has developed into a mature, highly internationalised industry supplied by producers from around the world.

What was once a relatively limited patient-access programme has turned into a mature and highly internationalised industry.

Primary source description of Germany’s medical cannabis market

Canada remains the anchor supplier

Among those exporting countries, Canada still holds the leading position. The source attributes that staying power to years of investment in export capacity and in the regulatory certifications needed to reach European pharmaceutical markets. Supporting reporting adds a clearer market share estimate: Canadian producers supplied about 53% of the Q1 2026 volume.

Three markers from the current snapshot help explain how concentrated this market has become:

That contrast with the United Kingdom, which is outside the European Union, is one of the starkest figures in the source material. The UK is commonly described as Europe’s second-largest medical cannabis market, yet its cited 2025 imports of about 30 tonnes are far below Germany’s most recent 12-month total of more than 218 tonnes.

Plotted side by side, the gap is hard to miss:

Why the quarter eased from late 2025 without shrinking the market story

The primary source also notes an important nuance: Q1 2026 imports were lower than the revised figures recorded at the end of 2025. On its face, that might look like a cooling market. But the source points to a more complicated explanation, one rooted in where supply is now coming from rather than in any clear evidence of collapsing patient demand.

The demand question is more complicated

Germany’s 2024 cannabis reform widened the legal ecosystem around medical access. If domestic production is rising and some adults are obtaining cannabis through other lawful routes, import volumes can soften while the overall market remains broad and active.

The source points to three developments that may help explain the shift:

• Germany’s Cannabis Act, the CanG, removed production quotas in 2024 that had previously limited commercial cultivation.
• Adults have been allowed to grow up to three plants at home since April 2024.
• Non-profit cultivation associations, often called cannabis clubs, have been allowed to cultivate and distribute to registered members since July 2024.

Domestic cultivation is the most direct part of that story. The source says local capacity has kept increasing since the quota system was removed, allowing German producers to cover a growing share of patient demand that had previously depended on imports. At the same time, home grow and clubs add legal alternatives that may supplement or, for some people, partly replace pharmacy purchases.

The sequence of reforms and market expansion looks like this:

The cultivation side of that transition can also be pictured more concretely:

A huge market, but patient access is still a live policy question

The import figures show scale, but they do not settle the future of access. In Germany, pressure is already building around reimbursement rules. In DHV’s submission on the draft GKV savings law, the advocacy group argues that removing cannabis flowers from statutory health insurance reimbursement would undermine care and could even increase overall costs. That debate has already moved into mainstream politics, as Cannabivo reported earlier on the first Bundestag debate on a reimbursement cutoff for cannabis flowers.

That matters because a market this large is still sensitive to the terms on which patients can actually obtain products. The primary source suggests that some people may now complement or replace pharmacy purchases with home cultivation, but it also makes clear that there are no official data showing how many medical users have taken that path.

The patient-access side of the story looks less like a freight terminal and more like everyday healthcare administration:

For the moment, the safer reading is that Germany’s medical system remains extremely large while the channels around it are multiplying. That combination can keep the overall ecosystem broad even if import patterns become less one-directional than they were when pharmacies and foreign suppliers carried almost the whole load.

What Germany’s import data say about the wider European Union market

For the European Union, Germany’s import total is important not because it resolves the cannabis question, but because it shows how large a regulated medical channel can become inside a region where the wider cannabis economy is still dominated by illicit supply and uneven national rules.

As Cannabivo noted in our earlier coverage of the EU drug report, Europe’s cannabis picture is becoming more fragmented rather than less. DW’s summary of the EUDA 2026 report says the illicit cannabis market in the EU is still worth about €12 billion, and that cannabis accounted for 68% of roughly one million illegal-drug seizures in the bloc in 2024.

That broader context makes Germany’s medical figures more significant, not less. One member state has created a pharmacy-based system large enough to absorb more than 50 tonnes in a quarter, while the Union around it continues to wrestle with illicit trade, regulatory fragmentation and diverging national reform paths.

Taken together, the numbers point to three EU-level conclusions:

• Legal medical demand inside the European Union can reach industrial scale when a large member state builds a stable pharmacy channel.
• Cross-border supply remains central, even where domestic cultivation is starting to grow faster.
• Reform does not move in a single direction: medical imports can surge while other parts of the cannabis market remain tightly contested or largely illicit.

Reader questions about the 50-tonne quarter

The current figures answer some obvious questions, but they also leave a few limits worth stating plainly: